0001193125-24-030677.txt : 20240212 0001193125-24-030677.hdr.sgml : 20240212 20240209213453 ACCESSION NUMBER: 0001193125-24-030677 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240207 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cano Health, Inc. CENTRAL INDEX KEY: 0001800682 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39289 FILM NUMBER: 24617161 BUSINESS ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 BUSINESS PHONE: 2034227700 MAIL ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 FORMER COMPANY: FORMER CONFORMED NAME: Jaws Acquisition Corp. DATE OF NAME CHANGE: 20200121 8-K 1 d780400d8k.htm FORM 8-K Form 8-K
NONE 0001800682 false 0001800682 2024-02-07 2024-02-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 9, 2024 (February 7, 2024)

 

 

 

LOGO

Cano Health, Inc.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-39289

 

Delaware   98-1524224

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification No.)

 

9725 NW 117th Avenue, Miami, FL   33178
(Address of principal executive offices)   (Zip Code)

(855) 226-6633

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A common stock, $0.01 par value per share   CANOQ   *

 

*

On February 5, 2024, the New York Stock Exchange (“NYSE”) determined to commence proceedings to delist and immediately suspended the registrant’s Class A common stock, par value $0.01 per share, from trading on the NYSE. The registrant’s common stock began trading on the OTC Pink Marketplace on February 6, 2024 under the symbol “CANOQ”.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Explanatory Note

As previously disclosed in a Current Report on Form 8-K filed by the Company on February 5, 2024 (the “Previous 8-K”), on February 4, 2024, Cano Health, Inc. (the “Company”) and certain of its direct and indirect subsidiaries (such subsidiaries, together with the Company, the “Debtors”) commenced filing voluntary petitions (the “Chapter 11 Cases”) in the U.S. Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) seeking relief under Chapter 11 of the U.S. Code (the “Bankruptcy Code”). The Chapter 11 Cases are being jointly administered under Case No. 24-10164. The Debtors continue to operate their business and manage their properties as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court.

Item 3.03 Material Modification of Rights of Security Holders.

The information set forth below in Item 7.01 of this Current Report on Form 8-K (this “Form 8-K”) regarding the Bankruptcy Court’s Interim Order (I) Establishing Notification Procedures and Approving Restrictions on Certain Transfers of Interests in the Debtors and (II) Granting Related Relief (Docket No. 8) (the “Interim NOL Order”) is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

Interim NOL Order

In connection with the commencement of their Chapter 11 Cases, the Debtors filed a number of motions with the Bankruptcy Court. Among these was a motion to establish certain procedures to protect any potential value of the Company’s net operating loss carryforwards and other tax attributes (the “NOLs,” and such motion, the “NOL Motion”). On February 7, 2024, the Bankruptcy Court entered the Interim NOL Order. All capitalized terms not defined herein have the meanings ascribed to such terms in the Stock Procedures (as defined below and attached hereto as Exhibit 99.2).

The Interim NOL Order establishes certain procedures (the “Stock Procedures”) with respect to direct and indirect trading and transfers of shares of the Company’s Class A common stock (the “Common Stock”) in order to protect any potential value of the Company’s NOLs for use in connection with the reorganization. As approved on an interim basis, in certain circumstances, the Stock Procedures restrict transactions involving, and require notices of the holdings of and proposed transactions by, any person or group of persons that is or, as a result of such a transaction, would become, a “Substantial Stockholder” of the Company’s Common Stock. The Debtors may, in consultation with the Ad Hoc First Lien Group, waive, in writing, any and all restrictions, stays, and notification procedures set forth in the Stock Procedures. For purposes of the Stock Procedures, a “Substantial Stockholder” is any person or entity (within the meaning of applicable regulations promulgated by the U.S. Department of the Treasury, including certain persons making a coordinated acquisition of stock) that beneficially owns (including Options to acquire and direct or indirect ownership) at least 225,509 shares of Common Stock (representing approximately 4.75% of all issued and outstanding shares of the Company’s Common Stock as of the petition date in the Chapter 11 Cases). For the avoidance of doubt, by operation of the definition of beneficial ownership, an owner of an Option to acquire Common Stock may be treated as the owner of such Common Stock. Any prohibited acquisition or other transfer of Common Stock (including directly or indirectly, and Options to acquire beneficial ownership of Common Stock) will be null and void ab initio and may lead to contempt, compensatory damages, punitive damages, or sanctions being imposed by the Bankruptcy Court. A hearing to consider entry of an order granting the relief requested in the NOL Motion on a final basis shall be held on March 7, 2024 at 10:00 a.m. (Eastern Time).

This same information may also be found at https://www.kccllc.net/CanoHealth, a website administered by Kurtzman Carson Consultants LLC, the Debtors’ Court-approved claims agent, and on the docket of the Chapter 11 Cases, Docket No. 92, which can be accessed via PACER at https://pacer.gov. The information on this website and docket is not incorporated by reference into, and does not constitute part of, this Current Report on Form 8-K.

The foregoing summary of the Interim NOL Order and the Stock Procedures is qualified in its entirety by reference to the notice of the Interim NOL Order (the “Notice of Order”) and the Stock Procedures, respectively, copies of which are attached hereto as Exhibits 99.1 and 99.2 and incorporated by reference herein.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements relate to future events and involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and could materially affect actual results, performance or achievements. These forward-looking statements generally can be identified by words such as “will,” “shall,” “may,” “anticipates,” “forecasts,” “plans,” “seeks,” or other words or phrases of similar import. Such statements include, without limitation, statements regarding: (i) the Restructuring Support Agreement between the Company, certain of its direct and indirect subsidiaries and the lenders party thereto, dated as of February 4, 2024 (the “RSA”), the transactions contemplated thereby, and the expected benefits thereof, including that it will enable the Company to substantially reduce its debt and position the Company to achieve long-term success and maximize value; (ii) the Company’s Chapter 11 Cases, including, without limitation, the outcome thereof and the Company’s expectations as to receipt of and timing for the Bankruptcy Court approvals and the timing of its emergence from the proceedings, as well as the expected benefits of the proceedings, such as that they will strengthen the Company’s financial condition, position the Company to advance its ongoing transformation plan that is designed to significantly reduce costs, enhance productivity, and improve cash flow, ensure patients continue to receive high-quality care across medical centers and improve health outcomes for patients at a lower cost; (iii) the availability of liquidity from the Company’s debtor-in-possession financing, including the DIP Credit Agreement, and the various conditions to which such debtor-in-possession financing is subject and the risk that these conditions may not be satisfied for various reasons, including for reasons outside of the Company’s control, as well as the Company’s planned uses of such funds, including, without limitation that the new capital will provide sufficient liquidity to support the Company’s ongoing operations throughout the restructuring process; (iv) the Company’s execution of one or more aspects of its Transformation Plan, including the benefits from such activities, including our expectations regarding achieving approximately $290 million of cost reductions by the end of 2024; and (v) the Company’s anticipated performance, operations, financial strength, potential, and prospects for long-term shareholder value creation, anticipated results of operations, including our business strategies, our projected costs, prospects and plans, and other aspects of our operations or operating results. It is uncertain whether any of the events anticipated by the forward-looking statements will occur, or, if any of them do, what impact they will have on our results of operations and financial condition. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, changes in market or industry conditions, the regulatory environment, competitive conditions, and/or consumer receptivity to our services; changes in our strategy, future operations, prospects and plans; our ability to realize expected financial results, including with respect to patient membership, total revenue and earnings; our ability to predict and control our medical cost ratio; our ability to maintain our relationships with health plans and other key payors; our future capital requirements and sources and uses of cash, including funds to satisfy our liquidity needs; our ability to attract and retain members of management and our Board of Directors; and/or our ability to recruit and retain qualified team members and independent physicians. Actual results may also differ materially from such forward-looking statements for a number of other reasons, including those set forth in our filings with the SEC, including, without limitation, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 15, 2023, as amended by our Annual Report on Form 10-K/A, filed with the SEC on April 7, 2023 (the “2022 Form 10-K”), as well as our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC during 2023 and 2024 (which may be viewed on the SEC’s website at http://www.sec.gov or on our website at http://www.investors.canohealth.com/ir-home), as well as reasons including, without limitation, our experiencing delays or difficulties in, and/or unexpected or less than anticipated results from its efforts to (i) successfully pursue the Chapter 11 Cases; (ii) less than expected benefits from the RSA; (iii) less than expected access to liquidity and greater than anticipated costs and expenses; (iv) less than expected cost reductions and/or any of the other expected benefits from its Transformation Plan, such as due to higher than expected costs and charges to achieve one or more aspects of such plan or delays in achieving such benefits; and/or (v) difficulties and/or delays in consummating one or more transactions arising from its pursuit of strategic alternatives. For a detailed discussion of other risks and

uncertainties that could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, please refer to our filings with the SEC, including, without limitation, our 2022 Form 10-K and our other SEC filings noted above. Factors other than those listed above could also cause our results to differ materially from expected results. Forward-looking statements speak only as of the date they are made and, except as required by law, we undertake no obligation or duty to publicly update or revise any forward-looking statement, whether to reflect actual results of operations; changes in financial condition; changes in general U.S. or international economic, industry conditions; changes in estimates, expectations or assumptions; or other circumstances, conditions, developments or events arising after the issuance of this Current Report on Form 8-K. Additionally, the business and financial materials and any other statement or disclosure on or made available through the Company’s websites or other websites referenced herein shall not be incorporated by reference into this Current Report on Form 8-K.

The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Cases. Holders of shares of the Company’s Class A common stock could experience a complete loss on their investment, depending on the outcome of the Chapter 11 Cases.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The exhibits listed on the Exhibit Index are incorporated herein by reference.

Exhibit Index

 

Exhibit No.

   

Description

99.1    Notice of Order, dated as of February 7, 2024
99.2    Stock Procedures
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      CANO HEALTH, INC.
February 9, 2024     By:  

/s/ Mark D. Kent

      Mark D. Kent
      Chief Executive Officer
 EX-99.1 2 d780400dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

ATTENTION DIRECT AND INDIRECT HOLDERS OF, AND PROSPECTIVE HOLDERS OF STOCK ISSUED BY CANO HEALTH, INC.:

Upon the motion, dated February 5, 2024 (the “Motion”) of Cano Health, Inc. and certain of its subsidiaries, as debtors and debtors in possession in the chapter 11 cases (collectively, the “Debtors”) captioned as In re Cano Health, Inc., et al., No. 24-10164 (KBO) (the “Chapter 11 Cases”), on February 7, 2024, the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), having jurisdiction over the Chapter 11 Cases, entered an interim order establishing procedures (the “Stock Procedures”) with respect to transfers in the beneficial ownership (including directly or indirectly) of shares of Class A common stock of Cano Health, Inc. (“Common Stock”) and options to acquire beneficial ownership of Common Stock, and scheduling a hearing on a final order with respect to such Stock Procedures.

In certain circumstances, the Stock Procedures restrict transactions involving, and require notices of the holdings of and proposed transactions by, any person, group of persons, or entity that either (i) is a Substantial Stockholder of the Common Stock or (ii) as a result of such a transaction, would become a Substantial Stockholder of the Common Stock. For purposes of the Stock Procedures, a “Substantial Stockholder” is any person or entity (within the meaning of applicable regulations promulgated by the U.S. Department of the Treasury, including certain persons making a coordinated acquisition of stock) that beneficially owns (including options to acquire and direct or indirect ownership) at least 225,509 shares of Common Stock (representing approximately 4.75% of all issued and outstanding shares of Common Stock as of the Petition Date). Any prohibited acquisition or other transfer of Common Stock (including options to acquire beneficial ownership of Common Stock) will be null and void ab initio and may lead to contempt, compensatory damages, punitive damages, or sanctions being imposed by the Bankruptcy Court.

The Stock Procedures, as approved on an interim basis and as requested on a final basis, are available on the website of Kurtzman Carson Consultants LLC, the Debtors’ Court-approved claims agent, located at https://www.kccllc.net/CanoHealth, and on the docket of the Chapter 11 Cases, Docket No. 92, which can be accessed via PACER at https://pacer.gov.

A direct or indirect holder of, or prospective holder of, Common Stock that may be or become a Substantial Stockholder should consult the Stock Procedures.

PLEASE TAKE NOTICE that the final hearing on the Motion shall be held on March 7, 2024, at 10:00 a.m. (Prevailing Eastern Time), and any objections or responses to the Motion shall be in writing, filed with the Court, and served upon: (i) proposed attorneys for the Debtors, Weil, Gotshal & Manges LLP, 767 Fifth Avenue, New York, New York 10153 (Attn: Gary T. Holtzer, Esq. (gary.holtzer@weil.com), Jessica Liou, Esq. (jessica.liou@weil.com), Matthew P. Goren, Esq. (matthew.goren@weil.com), and Rachael Foust, Esq. (rachael.foust@weil.com)); (ii) proposed co-counsel for the Debtors, Richards, Layton & Finger, P.A., 920 North King Street, Wilmington, Delaware 19801 (Attn: Michael J. Merchant, Esq. (merchant@RLF.com), and Amanda R. Steele, Esq. (steele@rlf.com)); (iii) counsel to the Ad Hoc First Lien Group: Gibson, Dunn & Crutcher LLP, 200 Park Ave, New York, NY 10166 (Attn: Scott J. Greenberg, Esq. (SGreenberg@gibsondunn.com), Michael J. Cohen, Esq. (MCohen@gibsondunn.com), and Christina M. Brown, Esq. (christina.brown@gibsondunn.com)) and Pachulski, Stang, Ziehl &

 

Jones LLP, 919 North Market Street #1700, Wilmington, Delaware 19801 (Attn: Laura Davis Jones, Esq. (ljones@pszjlaw.com) and James O’Neill, Esq. (joneill@pszjlaw.com)); (iv) counsel to the Agent under the CS Credit Agreement: Freshfields Bruckhaus Deringer US LLP, 601 Lexington Avenue, New York, NY 10022 (Attn: Mark F. Liscio, Esq. (mark.liscio@freshfields.com) and Scott D Talmadge, Esq. (scott.talmadge@freshfields.com)); (v) counsel to the Agent under the Side-Car Credit Agreement: Proskauer Rose LLP, 70 West Madison, Suite 3800, Chicago, IL 60602 (Attn: Evan Palenschat, Esq. (EPalenschat@proskauer.com)); (vi) U.S. Bank National Association, West Side Flats 60 Livingston Ave. EP-MN-WS3C Saint Paul, MN 55107 (Attn: Global Corporate Trust Services), the Indenture Trustee under the Senior Note Indenture; and (vii) the Office of the United States Trustee for the District of Delaware, 844 N. King Street, Wilmington, Delaware 19801 (Attn: Benjamin A. Hackman, Esq. (Benjamin.A.Hackman@usdoj.gov) and Jon Lipshie, Esq. (Jon.Lipshie@usdoj.gov)); in each case by no later than 4:00 p.m. (Prevailing Eastern Time) on February 29, 2024.

[Remainder of Page Intentionally Left Blank]

 

2

PLEASE TAKE FURTHER NOTICE that the requirements set forth in the Stock Procedures are in addition to the requirements of any applicable securities, corporate, and other laws and do not excuse non-compliance therewith.

 

Dated: 

Wilmington, Delaware

  February 7, 2024

 

/s/ Amanda R. Steele

RICHARDS, LAYTON & FINGER, P.A.
Mark D. Collins (No. 2981)
Michael J. Merchant (No. 3854)

Amanda R. Steele (No. 5530)

920 North King Street

Wilmington, Delaware 19801
Telephone: 302-651-7700

Email: collins@rlf.com

 merchant@rlf.com

 steele@rlf.com

-and-
WEIL, GOTSHAL & MANGES LLP
Gary T. Holtzer (admitted pro hac vice)
Jessica Liou (admitted pro hac vice)

Matthew P. Goren (admitted pro hac vice)

767 Fifth Avenue

New York, New York 10153
Telephone: (212) 310-8000
Emails: gary.holtzer@weil.com

 jessica.liou@weil.com

 matthew.goren@weil.com

Proposed Attorneys for the Debtors and the Debtors in Possession

 

 

3

EX-99.2 3 d780400dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

     x   
In re    :    Chapter 11
   :   
CANO HEALTH, INC., et al.,    :    Case No. 24-10164 (KBO)
   :   
   :   
Debtors.1    :    (Jointly Administered)
     x   

NOTICES, RESTRICTIONS, AND OTHER PROCEDURES

REGARDING OWNERSHIP AND TRANSFERS OF INTERESTS IN THE DEBTORS

TO ALL PERSONS OR ENTITIES THAT BENEFICIALLY OWN EQUITY INTERESTS IN THE DEBTORS:

Pursuant to that certain Interim Order Pursuant to 11 U.S.C. §§ 362 and 105(a) (i) Establishing Notification Procedures and Approving Restrictions on Certain Transfers of Interests in the Debtors and (ii) Granting Related Relief (the “Interim Order”) entered by the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on February 7, 2024, Docket No. 92, the following restrictions, notification requirements, and/or other procedures (collectively, the “Stock Procedures”) apply to all trading and transfers in the beneficial ownership of Common Stock (including directly or indirectly, and including Options to acquire beneficial ownership of Common Stock).2

 

1

The last four digits of Cano Health, Inc.’s tax identification number are 4224. A complete list of the Debtors in the chapter 11 cases may be obtained on the website of the Debtors’ claims and noticing agent at https://www.kccllc.net/CanoHealth. The Debtors’ mailing address is 9725 NW 117th Avenue, Miami, Florida 33178.

2

Capitalized terms used, but not otherwise defined, herein shall have the same meanings ascribed to such terms in the Interim Order.

A.

Common Stock Restrictions

 

(1)

Definitions. For purposes of these Stock Procedures, the following terms have the following meanings:

(a) “Common Stock” shall mean any shares of Class A common stock issued by Cano Health, Inc. (“CHI”). For the avoidance of doubt, by operation of the definition of beneficial ownership, an owner of an Option to acquire Common Stock may be treated as the owner of such Common Stock.

(b) “Option” shall mean any contingent purchase, warrant, convertible debt, put, stock subject to risk of forfeiture, contract to acquire stock, including, without limitation, any redemption right pursuant to that certain Second Amended and Restated Limited Liability Company Agreement of Primary Care (ITC) Intermediate Holdings, LLC, dated as of June 3, 2021, and any warrant to purchase issued pursuant to that certain Warrant Agreement, by and between CHI and Continental Stock Transfer & Trust Company, a New York corporation, dated as of May 18, 2020, or similar interest regardless of whether it is contingent, subject to vesting or otherwise not currently exercisable.

(c) “Beneficial Ownership” (and any variation thereof including “beneficially owns”) of Common Stock and Options to acquire Common Stock shall be determined in accordance with section 382 of the Tax Code, the regulations promulgated by the U.S. Department of the Treasury under the Tax Code (the “Treasury Regulations”), rulings issued by the Internal Revenue Service (the “IRS”), and the rules described herein, and thus shall include, without limitation, (A) direct and indirect ownership, determined without regard to any rule that treats stock of an entity as to which the constructive ownership rules apply as no longer owned by that entity (e.g., a holding company would be considered to beneficially own all stock owned or acquired by its subsidiaries), (B) ownership by a holder’s family members, (C) ownership by any group of persons acting pursuant to a formal or informal understanding among themselves to make a coordinated acquisition of stock, and (D) to the extent set forth in Treasury Regulations section 1.382-4, the ownership of an Option to acquire beneficial ownership of Common Stock.

(d) “Entity” shall mean any “entity” as such term is defined in Treasury Regulations section 1.382-3(a), including a group of persons who have a formal or informal understanding among themselves to make a coordinated acquisition of stock.

(e) “Substantial Stockholder” shall mean any Entity or person that beneficially owns at least 225,509 shares of Common Stock (representing approximately 4.75% of all issued and outstanding shares of Common Stock as of the Petition Date). For the avoidance of doubt, by operation of the definition of beneficial ownership, an owner of an Option to acquire Common Stock may be treated as the owner of such Common Stock.

 

(2)

Notice of Substantial Ownership. Any person or Entity that beneficially owns, at any time on or after the Petition Date, Common Stock in an amount sufficient to qualify such person or Entity as a Substantial Stockholder shall file with the Court and serve via first class mail and email or fax (if applicable) upon (i) the Debtors, 9725 NW 117th Avenue, Miami, Florida 33178 (Attn: Eladio Gil (eladio.gil@canohealth.com))]; (ii) proposed attorneys for the Debtors, Weil, Gotshal & Manges LLP, 767 Fifth Avenue, New York, New York 10153 (Attn: Gary T. Holtzer, Esq. (gary.holtzer@weil.com), Jessica Liou, Esq. (jessica.liou@weil.com), Matthew P. Goren, Esq. (matthew.goren@weil.com), and Rachael Foust, Esq. (rachael.foust@weil.com)) and Richards, Layton & Fingers, One

 

2

  Rodney Square, 920 North King Street, Wilmington, DE 19801 (Attn: Mark D. Collins , Esq. (collins@rlf.com), Michael J. Merchant, Esq. (merchant@rlf.com), and Amanda R. Steele, Esq. (steele@rlf.com)); (iii) attorneys for the Ad Hoc First Lien Group: Gibson, Dunn & Crutcher LLP, 200 Park Ave, New York, NY 10166 (Attn: Scott J. Greenberg, Esq. (SGreenberg@gibsondunn.com), Michael J. Cohen, Esq. (MCohen@gibsondunn.com), and Christina M. Brown, Esq. (christina.brown@gibsondunn.com)) and Pachulski, Stang, Ziehl & Jones LLP, 919 North Market Street #1700, Wilmington, Delaware 19801 (Attn: Laura Davis Jones, Esq. (ljones@pszjlaw.com) and James O’Neill, Esq. (joneill@pszjlaw.com)); and (iv) attorneys for any statutory committee of unsecured creditors appointed in these cases (collectively, the “Disclosure Parties”) a notice of such person’s or Entity’s substantial ownership (a “Substantial Stock Ownership Notice”), in substantially the form annexed to the Proposed Orders as Exhibit 2, which describes specifically and in detail such person’s or Entity’s beneficial ownership of Common Stock, on or before the date that is the later of (x) twenty (20) calendar days after the entry of the order granting the requested relief or (y) ten (10) business days after such person or Entity qualifies as a Substantial Stockholder. At the election of the Substantial Stockholder, the Substantial Stock Ownership Notice to be filed with the Court (but not the Substantial Stock Ownership Notice that is served upon the Disclosure Parties) may be redacted to exclude all but the last four (4) digits of the Substantial Stockholder’s taxpayer identification number.

 

(3)

Acquisition of Common Stock. At least twenty (20) business days prior to the proposed date of any transfer in the beneficial ownership of Common Stock (including directly or indirectly, and including the grant or other acquisition of Options to acquire beneficial ownership of Common Stock) or exercise of any Option to acquire beneficial ownership of Common Stock that would result in an increase in the amount of Common Stock beneficially owned by any person or Entity that currently is or, as a result of the proposed transaction, would be a Substantial Stockholder (a “Proposed Acquisition Transaction”), such acquiring or increasing person or Entity or Substantial Stockholder (a “Proposed Transferee”) shall file with the Court and serve via first class mail and email or fax (if applicable) upon the Disclosure Parties a notice of such Proposed Transferee’s intent to purchase, acquire, or otherwise accumulate Common Stock (an “Acquisition Notice”), in substantially the form annexed to the Proposed Orders as Exhibit 3, which describes specifically and in detail the Proposed Acquisition Transaction. At the election of the Proposed Transferee, the Acquisition Notice to be filed with the Court (but not the Acquisition Notice that is served upon the Disclosure Parties) may be redacted to exclude all but the last four (4) digits of the Proposed Transferee’s taxpayer identification number.

 

(4)

Disposition of Common Stock. At least twenty (20) business days prior to the proposed date of any transfer or other disposition in the beneficial ownership of Common Stock (including directly or indirectly, and Options to acquire beneficial ownership of Common Stock) that would result in either a decrease in the amount of Common Stock beneficially owned by a Substantial Stockholder or a person or Entity ceasing to be a Substantial Stockholder (a “Proposed Disposition Transaction” and, together with a Proposed Acquisition Transaction, a “Proposed Transaction”), such selling or decreasing person

 

3

  or Entity or Substantial Stockholder (a “Proposed Transferor”) shall file with the Court and serve via first class mail and email or fax (if applicable) upon the Disclosure Parties a notice of such Proposed Transferor’s intent to sell, trade, or otherwise transfer its beneficial ownership of Common Stock (a “Disposition Notice” and, together with an Acquisition Notice, a “Trading Notice”), in substantially the form annexed to the Proposed Orders as Exhibit 4, which describes specifically and in detail the Proposed Disposition Transaction. At the election of the Proposed Transferor, the Disposition Notice to be filed with the Court (but not the Disposition Notice that is served upon the Disclosure Parties) may be redacted to exclude all but the last four (4) digits of the Proposed Transferor’s taxpayer identification number.

 

(5)

Certain Pre-Approval Exceptions. For the avoidance of doubt, a pre-transfer Trading Notice is not required to be filed in connection with a transfer of beneficial ownership of Common Stock (i) from a person to an entity that is disregarded for U.S. federal income tax purposes as being separate from the person (a “Disregarded Entity”), or from such Disregarded Entity to such person; (ii) from a person to a trust whose assets are treated as being solely owned by such person for U.S. federal income tax purposes (a “Grantor Trust”), or from such Grantor Trust to such person; (iii) from a Disregarded Entity to any one or more other Disregarded Entities or Grantor Trusts if the same person is treated as the owner or taxpayer with respect to all of the assets of such Disregarded Entities or Grantor Trusts for U.S. federal income tax purposes; and (iv) from a Grantor Trust to any one or more other Grantor Trusts or Disregarded Entities if the same person is treated as the owner or taxpayer with respect to all of the assets of such Grantor Trusts and Disregarded Entities for U.S. federal income tax purposes. However, in the event of any such transfer for which a Trading Notice would otherwise have been required if the Disregarded Entities or Grantor Trusts involved had not been so disregarded for U.S. federal income tax purposes, that transferor or transferee shall no more than ten (10) business days after the date of transfer serve via first class mail and email or fax (if applicable) upon the Disclosure Parties a notice substantially similar to the equivalent Trading Notice (a “Disregarded Transfer Notice”); however, absent gross negligence or reckless or intentional disregard, the failure to timely file such notice shall not be subject to sanctions.

 

(6)

Objection Procedures. The Debtors and the other Disclosure Parties shall have fifteen (15) business days after the filing of a Trading Notice (the “Objection Period”) to file with the Court and serve on a Proposed Transferee or a Proposed Transferor, as the case may be, an objection (each, an “Objection”) to any Proposed Transaction described in such Trading Notice. If the Debtors or another Disclosure Party files an Objection by the expiration of the Objection Period (the “Objection Deadline”), then the applicable Proposed Transaction shall not be effective unless approved by a final and non-appealable order of the Court. If the Debtors or the other Disclosure Parties do not file an Objection by the Objection Deadline or if the Debtors provide written authorization to the Proposed Transferee or the Proposed Transferor, as the case may be, approving the Proposed Transaction prior to the Objection Deadline, then such Proposed Transaction may proceed solely as specifically described in the applicable Trading Notice. Any further Proposed Transaction must be the subject of an additional Trading Notice and Objection Period.

 

4

B.

Noncompliance with the Stock Procedures

Any acquisition, disposition, or trading in the beneficial ownership of Common Stock (including directly or indirectly, and Options to acquire beneficial ownership of Common Stock) in violation of these Stock Procedures (other than, for the avoidance of doubt, the Disregarded Transfer Notice) shall be null and void ab initio pursuant to the Bankruptcy Court’s equitable powers under section 105(a) of the Bankruptcy Code. Furthermore, any person or Entity that acquires, disposes of, or trades in the beneficial ownership of Common Stock (including directly or indirectly, and Options to acquire beneficial ownership of Common Stock) in violation of the Stock Procedures may be subject to sanctions as provided by law.

 

C.

Debtors’ Right to Waive

The Debtors may, in consultation with the Ad Hoc First Lien Group, waive, in writing, any and all restrictions, stays, and notification procedures contained in this Notice.

 

Dated:

Wilmington, Delaware

 

February 8, 2024

 

/s/ Amanda R. Steele

RICHARDS, LAYTON & FINGER, P.A.
Mark D. Collins (No. 2981)
Michael J. Merchant (No. 3854)
Amanda R. Steele (No. 5530)
920 North King Street
Wilmington, Delaware 19801
Telephone: 302-651-7700
Email:   collins@rlf.com
  merchant@rlf.com
  steele@rlf.com
-and-
WEIL, GOTSHAL & MANGES LLP
Gary T. Holtzer (admitted pro hac vice)
Jessica Liou (admitted pro hac vice)
Matthew P. Goren (admitted pro hac vice)
767 Fifth Avenue
New York, New York 10153
Telephone: (212) 310-8000
Emails:   gary.holtzer@weil.com
  jessica.liou@weil.com
  matthew.goren@weil.com
Proposed Attorneys for the Debtors
and the Debtors in Possession

 

5

EX-101.SCH 4 canoq-20240207.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 canoq-20240207_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 1 Entity Address City Or Town Entity Address City Or Town Entity Address State Or Province Entity Address State Or Province Entity Address Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 6 canoq-20240207_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g780400g0210024520513.jpg GRAPHIC begin 644 g780400g0210024520513.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 07, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 07, 2024
Entity Registrant Name Cano Health, Inc
Entity File Number 001-39289
Entity Incorporation State Country Code DE
Entity Tax Identification Number 98-1524224
Entity Address Address Line 1 9725 NW 117th Avenue
Entity Address City Or Town Miami
Entity Address State Or Province FL
Entity Address Postal Zip Code 33178
City Area Code 855
Local Phone Number 226-6633
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A common stock, $0.01 par value per share
Trading Symbol CANOQ
Security Exchange Name NONE
Entity Emerging Growth Company false
Entity Central Index Key 0001800682
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000001 - Document - Document and Entity Information Sheet http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports canoq-20240207.xsd canoq-20240207_lab.xml canoq-20240207_pre.xml d780400d8k.htm g780400g0210024520513.jpg http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d780400d8k.htm": { "nsprefix": "canoq", "nsuri": "http://www.canohealth.com/20240207", "dts": { "schema": { "local": [ "canoq-20240207.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "canoq-20240207_lab.xml" ] }, "presentationLink": { "local": [ "canoq-20240207_pre.xml" ] }, "inline": { "local": [ "d780400d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-07_to_2024-02-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d780400d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-07_to_2024-02-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d780400d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "terseLabel": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.canohealth.com//20240207/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001193125-24-030677-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-030677-xbrl.zip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d780400d8k_htm.xml IDEA: XBRL DOCUMENT 0001800682 2024-02-07 2024-02-07 NONE 0001800682 false 8-K 2024-02-07 Cano Health, Inc 001-39289 DE 98-1524224 9725 NW 117th Avenue Miami FL 33178 855 226-6633 false false false false Class A common stock, $0.01 par value per share CANOQ false